Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Genzyme completes purchase of Synvisc sales and marketing rights
February 3rd, 2005
Genzyme Corp. (GENZ) announced that it has completed the transaction to buy back the sales and marketing rights to Synvisc (hylan G-F 20) in the United States and five European countries from Wyeth (WYE). The cash transaction is accretive to Genzyme. Genzyme will now record all Synvisc end-user revenue in the U.S. and five European countries (Germany, Poland, Greece, Portugal, and the Czech Republic). Synvisc is a viscosupplementation product for the treatment of pain due to osteoarthritis of the knee. "This is a strategic franchise for Genzyme and one of our key areas of growth and investment," said Ann Merrifield, president of...
Source: Women's Health Weekly (2005-02-03)
|
